Head/Neck Cancer News

A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual care-based patient navigation for people with head and neck squamous cell carcinoma.

The shortage of generic chemotherapy drugs cisplatin and carboplatin that began in early 2023 did not increase short-term mortality rates among people with advanced cancer, according to results of a cohort study.

Despite focused efforts to improve the diversity of clinical trials, representation in research into head and neck cancer has become less equitable over the past decade, according to retrospective study results.

Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid cancer risk was observed in the first year after GLP-1 initiation, researchers reported.

Cancer incidence has continued to rise in the U.S. since the 1990s — particularly among women and younger adults, according to an American Cancer Society report.

Healio will present its fourth annual Disruptive Innovators Awards for oncology/hematology this spring.

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid.

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally advanced squamous cell carcinoma of the head and neck.

U.S. Surgeon General Vivek Murthy, MD, MBA, issued an advisory today that includes several recommendations designed to reduce the impact of alcohol on cancer incidence and mortality.